Skip to main content

LAVA Therapeutics NV

LVTXDelisted Nov 21, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001840748

LAVA Therapeutics NV was delisted on Nov 21, 2025; its insiders filed their last Form 4 on Nov 17, 2025; 21 institutions reported holding it in 13F filings for Q3 2025, worth $16.1M in total; no superinvestor held it.

13F holders, Q2 2024

Institutional positions in LAVA Therapeutics NV as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
19
0 vs. Q1 2024
Shares held
3.76M
−1.64K (0.0%) vs. Q1 2024
Total value
$6.77M
−$5.75M (−46.0%) vs. Q1 2024
New holders
3
5 more added
Sold out
3
4 more reduced

1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q1 2024: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting LVTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2024: 19 institutions
Q1 2021: 24 institutionsQ2 2021: 18 institutionsQ3 2021: 19 institutionsQ4 2021: 20 institutionsQ1 2022: 18 institutionsQ2 2022: 17 institutionsQ3 2022: 13 institutionsQ4 2022: 20 institutionsQ1 2023: 19 institutionsQ2 2023: 15 institutionsQ3 2023: 14 institutionsQ4 2023: 14 institutionsQ1 2024: 20 institutionsQ2 2024: 19 institutionsQ3 2024: 21 institutionsQ4 2024: 22 institutionsQ1 2025: 20 institutionsQ2 2025: 19 institutionsQ3 2025: 21 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ2 2024: $6.77M
Q1 2021: $139.1MQ2 2021: $95.5MQ3 2021: $48.6MQ4 2021: $44.3MQ1 2022: $35.2MQ2 2022: $22.8MQ3 2022: $34.1MQ4 2022: $26.3MQ1 2023: $11.2MQ2 2023: $11.7MQ3 2023: $8.47MQ4 2023: $9.22MQ1 2024: $12.5MQ2 2024: $6.77MQ3 2024: $5.99MQ4 2024: $6.15MQ1 2025: $10.2MQ2 2025: $10.6MQ3 2025: $16.1MQ4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding LVTX and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 202521$16.1M
Q2 202519$10.6M
Q1 202520$10.2M
Q4 202422$6.15M
Q3 202421$5.99M
Q2 202419$6.77M
Q1 202420$12.5M
Q4 202314$9.22M
Q3 202314$8.47M
Q2 202315$11.7M
Q1 202319$11.2M
Q4 202220$26.3M
Q3 202213$34.1M
Q2 202217$22.8M
Q1 202218$35.2M
Q4 202120$44.3M
Q3 202119$48.6M
Q2 202118$95.5M
Q1 202124$139.1M

Institutions, Q2 2024

Shares, value and share of portfolio for each institution holding LAVA Therapeutics NV; share changes are against Q1 2024.

Institutions holding LVTX in Q2 2024
InstitutionSharesValue% of portfolioChange in sharesAction
Redmile Group, LLC2,074,372$3.73M0.23%00.0%Unchanged
Bruce & Co., Inc.771,874$1.39M0.46%00.0%Unchanged
Sphera Funds Management Ltd.367,582$661.6K0.11%00.0%Unchanged
Two Sigma Investments, LP112,439$202.4K0.00%+30,408+37.1%Added
Falcon Edge Capital, LP87,397$157.3K0.05%−20,509−19.0%Reduced
Citadel Advisors LLC66,237$119.2K0.00%+66,237New
The PNC Financial Services Group, Inc.65,000$117.0K0.00%00.0%Unchanged
Pathway Financial Advisors LLC60,000$108.0K0.03%+46,000+328.6%Added
Two Sigma Advisers, LP31,700$57.1K0.00%+15,000+89.8%Added
XTX Topco Ltd30,807$55.5K0.00%+30,807New
Millennium Management LLC26,493$47.7K0.00%+6,465+32.3%Added
Walleye Capital LLC25,675$46.2K0.00%−128,991−83.4%Reduced
Morgan Stanley15,600$28.1K0.00%+5,400+52.9%Added
Geode Capital Management, LLC11,124$20.0K0.00%00.0%Unchanged
CIBC Private Wealth Group, LLC6,000$11.1K0.00%00.0%Unchanged
Tang Capital Management LLC5,109$9.20K0.00%+5,109New
TSFG, LLC400$1.00K0.00%00.0%Unchanged
Bank of America Corp400$7200.00%−15,011−97.4%Reduced
Simplex Trading, LLC226$00.00%−2,363−91.3%Reduced
Schonfeld Strategic Advisors LLC0$00.00%−18,300−100.0%Sold out
Two Sigma Securities, LLC0$00.00%−12,908−100.0%Sold out
UBS Group AG0$00.00%−8,980−100.0%Sold out
Cutler Group LP––––Not filed